Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hayashi, Keiichiro ^a,b   Michiue, Hiroyuki ^a   Yamada, Hiroshi ^a   Takata, Katsuyoshi ^a   Nakayama, Hiroki ^a   Wei, Fan Yan ^c   Fujimura, Atsushi ^a   Tazawa, Hiroshi ^a,b   Asai, Akira ^d   Ogo, Naohisa ^d   Miyachi, Hiroyuki ^a   Nishiki, Tei Ichi ^a   Tomizawa, Kazuhito ^c   Takei, Kohji ^a   Matsui, Hideki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; FOCAL ADHESION KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ANIMAL; BRAIN NEOPLASMS; CANCER STEM CELL; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG REPOSITIONING; DRUG SCREENING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; FLUVOXAMINE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961784473     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23372     Document Type: Article

References (40)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996 (2005).
2. Muldoon, L. L. et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25, 2295-2305 (2007).
3. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828 (2003).
4. Yuan, X. et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392-9400 (2004).
5. Singh, S. K. et al. Identification of human brain tumor initiating cells. Nature 432, 396-401 (2004).
6. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
7. Liu, G. et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5, 67 (2006).
8. Sottoriva, A. et al. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 70, 46-56 (2010).
9. Pollard, T. D., Borisy, G. G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 112, 453-465 (2003).
10. Nurnberg, A. et al. Nucleating actin for invasion. Nat Rev Cancer 11, 177-187 (2011).
11. Le Clainche, C., Carlier, M. F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev 88, 489-513 (2008).
12. Ashburn, T. T., Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683 (2004).
13. Andronis, C. et al. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 12, 357-368 (2011).
14. Corbett, A. et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 11, 833-846 (2012).
15. Egawa, T. et al. Neither the 5-HT1A-nor the 5-HT2-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on forced-swimming-induced immobility in mice. Jpn J Pharmacol 68, 71-75 (1995).
16. Ushijima, K. et al. Chronopharmacological study of antidepressants in forced swimming test of mice. J Pharmacol Exp Ther 315, 764-770 (2005).
17. Nave, B. T. et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344, 427-431 (1999).
18. Peterson, R. T. et al. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275, 7416-7423 (2000).
19. Bellis, S. L. Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem 270, 17437-17441 (1995).
20. Weiner, T. M. et al. Expression of focal adhesion kinase gene and invasive cancer. Lancet 342, 1024-1025 (1993).
21. Owens, L. V. et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55, 2752-2755 (1995).
22. Hecker, T. P. et al. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 62, 2699-2707 (2002).
23. Serrels, B. et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol 9, 1046-1056 (2007).
24. Golubovskaya, V. M. et al. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12, 162-172 (2013).
25. Nakamura, K. et al. Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies. Oncogene 20, 2626-2635 (2001).
26. Feng, J. et al. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279, 41189-41196 (2004).
27. Sarbassov, D. D. et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
28. Guertin, D. A. et al. Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007).
29. Huang, W. et al. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci 16, 441-448 (2013).
30. DiNitto, J. P. et al. Membrane and juxtamembrane targeting by PH and PTB domains. Biochim Biophys Acta 1761, 850-867 (2006).
31. Bozulic, L., Hemmings, B. A. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21, 256-261 (2009).
32. dos Remedios, C. G. et al. Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83, 433-473 (2003).
33. Bolo, N. R. et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23, 428-438 (2000).
34. Strauss, W. L. et al. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155, 380-384 (1998).
35. Caudill, J. S. et al. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. Am J Clin Oncol 34, 385-387 (2011).
36. Weber, G. F. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett 328, 207-211 (2013).
37. Munson, J. M. et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 4, 127-36 (2012).
38. Yamada, H. et al. Dynamic interaction of amphiphysin with N-WASP regulates actin assembly. J Biol Chem 284, 34244-34256 (2009).
39. Ueda, Y. et al. Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus. Biomaterials 33, 9061-9069 (2012).
40. Liang, C. C. et al. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2, 329-333 (2007).